Peter G. Schultz, Ph.D.
Chief Executive Officer
Peter G. Schultz graduated from Caltech in 1979 with a B.S. degree in Chemistry (summa cum laude) and continued there for his doctoral degree with Peter Dervan (in 1984). After a postdoctoral year at the Massachusetts Institute of Technology, he moved to the University of California, Berkeley, where he was a Professor of Chemistry, a Principal Investigator at the Lawrence Berkeley National Laboratory and an Investigator in the Howard Hughes Medical Institute. He moved to The Scripps Research Institute in 1999 where he is currently the Chief Executive Officer and Vice Chair. Schultz’s contributions to science include: (1) the discovery of catalytic antibodies, and their use to study fundamental mechanisms of biological and the immune system (2) the development and application of methods to expand the genetic code of living organisms; and (3) the development and application of molecular diversity technologies to problems in chemistry, biology and medicine. Schultz also established the Genomics Institute of the Novartis Research Foundation I 1999 (GNF; La Jolla, CA) and served as its Director until 2010 with some 600 FTE. GNF develops and applies state of the art high throughput chemical, proteomics, genomics and informatics technologies to the identification of novel genes and biological processes, as well as the development of new human therapeutics for cancer, immune, metabolic, cardiovascular and infectious disease. More recently, Schultz established Calibr, which is focused on translational research to create innovative medicines for major unmet medical needs. Schultz is the author of 500+ scientific publications, has trained over 300 coworkers and has received numerous awards including the Alan T. Waterman Award, NSF (1988), the ACS Award in Pure Chemistry (1990), the Wolf Prize in Chemistry (1994), the Paul Erhlich and Ludwig Darmstaedter Award (2002), the ACS Arthur C. Cope Award (2006), and the Solvay Prize (2013). Professor Schultz is a member of the National Academy of Sciences, USA (1993) and the Institute of Medicine of the National Academy of Sciences (1998) and he is active on many editorial and scientific advisory boards. He is a founder of Affymax Research Institute, Symyx Technologies, Syrrx, Kalypsys, Phenomix, Ilypsa, Ambrx, Wildcat Discovery Technologies, and Ardelyx, which have pioneered the application of molecular diversity technologies to challenges in energy, materials and human health.
Matt Tremblay, Ph.D.
Chief Operating Officer
As Chief Operating Officer and Secretary to the Board of Directors, Matt is responsible for the day to day operation of the institute, as well as external relationships with academic, foundation and commercial partners, and works closely with the CEO to develop corporate strategy and advance new business development opportunities. Matt’s group also manages internal research programs and scientific interactions with partner organizations. Matt facilitated the launch of a number of strategic initiatives at Calibr, including drug discovery collaborations with the Juvenile Diabetes Research Foundation, the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, and Pfizer. He has been involved with research at Calibr since its inception in April 2012, leading a team of biologists in the discovery of new therapeutic agents for metabolic, cardiovascular, and autoimmune diseases. Before joining Calibr, Matt led a group at the Genomics Institute of the Novartis Research Foundation (GNF) in drug discovery for type 1 diabetes. Matt earned his Ph.D. in chemistry from Columbia University in 2007 before spending two years as a postdoctoral fellow in Peter Schultz’s lab at The Scripps Research Institute.
Kelly San George
Chief Financial Officer
Kelly San George joined Calibr in August 2017, bringing more than 20 years of financial leadership experience in medical device manufacturing and laboratory diagnostics. Prior to joining Calibr, she was Chief Financial Officer of Ridge Diagnostics, Inc., an early stage neurodiagnostics laboratory. Kelly was formerly Director of Finance at Synergy Health, a $500 million global provider of medical sterilization services. She was previously Vice President of Finance and Administration at Bionostics, a $30 million medical device manufacturer of quality control solutions and also held roles as Controller and Treasurer. Kelly was a key player in the sale of the company to Ferraris Group PLC and subsequently held the top financial role for the UK group both while it was listed on the London Stock Exchange and while it transitioned back to private ownership. Kelly began her career in the banking industry in professional and managerial positions with what has become Bank of America. She holds an MBA from Southern New Hampshire University and a BS in Business Administration from the University of Massachusetts Lowell.